RankAlpha logo
Back to Rankings

BIAF

bioAffinityA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Q1 results showed strong CyPath Lung unit growth and rising test revenue, the May 27 patent allowance adds another IP datapoint, and the company still has clinical work in flight that could expand validation if commercialization momentum holds.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.0.
What can break
Clinical and commercialization milestones are early-stage and slow to translate into valuation support.
Momentum
100
Value
41
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.80 · Bull $2.40 · Bear $0.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Why
Momentum100 · Δ7d +0.0
Value41 · Δ7d -17.6
Sentiment48 · Δ7d -2.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
100
34% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-
Value
41
32% active weight
Current posture
7d trendSoftening
Δ7d
-17.6
Δ21d
+0.2
Sentiment
48
33% active weight
Current posture
7d trendImproving
Δ7d
-2.1
Δ21d
-
Why this grade

Composite grade A. Momentum 99.9 / Value 41.1 / Sentiment 48.1

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$7.94M
Beta
2.44
Shares Out
4.5M
P/E (TTM) · Derived
-0.1
P/S (TTM)
0.83
P/FCF (TTM) · Derived
-0.15
Rev YoY
-38.5%
EPS YoY
+2.2%
Gross Margin
+27.9%
Op Margin
-153.2%
Net Debt
-$73.7K
Current Ratio
3.65
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology